Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2027

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

GP+Penpulimab+Anlotinib

GP combine with penpulimab and anlotinib neoadjuvant therapy+CCRT+penpulimab adjuvant therapy

DRUG

GP+Penpulimab

GP combine with penpulimab neoadjuvant therapy+CCRT+penpulimab adjuvant therapy

Trial Locations (1)

Hai Qiang Mai, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER